Helix Achieves A Key Milestone in the Fight Against COVID-19!

Worldwide COVID-19 testing continues to ramp up consistently, predominantly using RT-PCR as the “gold standard”. However, more sensitive testing applications are now being introduced. We are proud to announce that Helix has received emergency use authorization (EUA) from the FDA for COVID-19 testing using next generation sequencing (NGS) with iSWAB-Microbiome as the collection method. Using NGS for COVID testing allows for greater in-depth interrogation of samples, leading to more accurate testing results and flexibility for the use of high-throughput automation.

Ultimately, what matters most about COVID-19 testing is that the viral RNA remains stable from point of collection to processing. If not transported with cold chain methods and processed within 48-72 hours, a positive sample that has been sitting in traditional VTM/MTM could end up yielding false-negative results due to RNA degradation. Our non-toxic iSWAB-Microbiome sample collection technology has proven to maintain viral RNA integrity for weeks after collection while also showing complete compatibility with multiple extraction chemistries, downstream applications, and automation platforms making it a perfect fit for COVID-19 sample collection and transport.

Read More Here: Helix COVID-19 NGS Test – EUA Summary